Seaport Therapeutics, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Seaport raised $260.0 million gross proceeds in May 2026 IPO, resulting in $427.3 million in total cash, equivalents, and investments as of June 30, 2026—expected to fund operations into 2029. Phase 2b BUOY-1 trial of GlyphAllo in major depressive disorder on track for 1H 2027 topline data; Phase 1 driving simulation trial expected 2H 2026. GlyphAgo Phase 1 showed 6.8-fold bioavailability improvement vs. unmodified drug; Phase 2a/2b trials planned for 2H 2026 and 1H 2027 respectively.
Why this rating
IPO proceeds ($260M gross, ~$427M total) represent ~188% of prior asset base ($227.7M), materially extending runway; clinical progress de-risks lead programs; routine near-term event for clinical-stage biotech but transformational for this company's capital position.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.